Astellas Pharma (4503) Stock Statistics & Valuation Metrics

Astellas Pharma has a market cap or net worth of $2.68T. The enterprise value is ¥3.30T.

Astellas Pharma has 1,809,663,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Astellas Pharma’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 16.27%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Astellas Pharma had revenue of 1.91T and earned 50.75B in profits. Earnings per share was 28.35.

In the last 12 months, operating cash flow was 182.81B and capital expenditures -77.97B, giving a free cash flow of 104.85B billion.

Astellas Pharma pays an annual dividend of ¥39, resulting in a dividend yield of 4.97%

Astellas Pharma upcoming earnings date is Jul 30, 2025, TBA (Confirmed).

Astellas Pharma as a current ratio of 1.13, with Debt / Equity ratio of 54.94%

In the past 12 months, Astellas Pharma has paid -19.51B in taxes.

Astellas Pharma EV to EBITDA ratio is 13.02, with an EV/FCF ratio of 19.64.

Astellas Pharma has $188.37B in cash and marketable securities with ¥831.43B in debt, giving a net cash position of $643.05B billion.

Gross margin is 78.25%, with operating margin of 13.37%, and net profit margin of 2.65%.

The average price target for Astellas Pharma is $1,749.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy